SHUKRAPHAR vs VIVOBIOT: Stock Comparison
SHUKRA PHARMACEUTICALS L is the larger company by market capitalisation. SHUKRA PHARMACEUTICALS L shows a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
SHUKRAPHAR leads 4; VIVOBIOT leads 0 of 7
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Price
| Metric | SHUKRAPHAR | VIVOBIOT |
|---|---|---|
| Live Price | ₹79.88 | ₹14.65 |
| Day Change | -0.03% | -0.75% |
| Volume | 51.81 L | 9,969 |
| 52-Week High | ₹84.2 | ₹20.94 |
| 52-Week Low | ₹40.06 | ₹12 |
| Distance from 52W High | -5.13% | -30.04% |
Valuation
| Metric | SHUKRAPHAR | VIVOBIOT |
|---|---|---|
| Market Cap | ₹3,494 Cr | ₹33 Cr |
| P/E Ratio | 79.48x | — |
| P/B Ratio | 29.55x | — |
| EPS | ₹0.3 | ₹0.08 |
| Book Value | ₹2.05 | ₹41.98 |
| Dividend Yield | 0.01% | 0% |
Growth
| Metric | SHUKRAPHAR | VIVOBIOT |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | 0% |
| EPS Growth (TTM YoY) | 0% | 0% |
| Qtr Sales Growth | 271.95% | 0% |
| Qtr Profit Growth | 742.72% | 0% |
Profitability & Leverage
| Metric | SHUKRAPHAR | VIVOBIOT |
|---|---|---|
| Net Margin | 0% | 0% |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | SHUKRAPHAR | VIVOBIOT |
|---|---|---|
| Promoter Holding | 51.15%▲ 0.19 pp | 30.62%▼ 4.81 pp |
| FII Holding | 0.44%▲ 0.44 pp | 0% |
| DII Holding | 0.22%▲ 0.11 pp | 0% |
| Public Holding | 48.2%▼ 0.72 pp | 69.38%▲ 4.81 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: SHUKRA PHARMACEUTICALS L and VIVO BIO TECH.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.